3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
2
Urothelial Cancer
1
Solid Tumors, KRAS Mutation
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
enzalutamide
33
Abiraterone Acetate
28
apalutamide
25
Radiotherapy
25
Prednisone
25
Magnetic Resonance Spectroscopy
25
Androgen Antagonists
24
Leuprolide
21
Radiosurgery
19
darolutamide
18
Docetaxel
17
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
15
Gonadotropin-Releasing Hormone
14
gallium 68 PSMA-11
12
Specimen Handling
12
Goserelin
12
pembrolizumab
11
Radiotherapy, Intensity-Modulated
11
Radiation
11
bicalutamide
10
abiraterone
10
Pluvicto
10
Carboplatin
9
Brachytherapy
9
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
9
relugolix
8
luprolide acetate gel depot
8
Standard of Care
8
Nivolumab
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Prostatic Neoplasms
×
Midazolam
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled